Analyst Commentary On Juno Therapeutics, Inc. (JUNO), Xencor, Inc. (XNCR)

Juno Therapeutics, Inc. (NASDAQ:JUNO) is gaining traction with investors, as evidenced by its 1.17 million shares volume. The daily trading volume average remained 2.64 million shares over the course of 3 months. The stock had opened the regular trading at $42.5 and managed a 1.09% price change to reach $43.53 through the close.

Juno Therapeutics, Inc. (JUNO) Analyst Opinion

Juno Therapeutics, Inc. has a consensus outperform rating from 14 Wall Street analysts, and the number of shares currently sold short amount to at least 10.48% of shares outstanding. The stock spiked 1.99% last month and is up 130.93 this year. Wall Street is only getting more bullish on the stock, with 9 of analysts who cover JUNO having a buy-equivalent rating. Analysts have placed a $39.06 price target on Juno Therapeutics, Inc., suggesting a -10.27% decline from recent close. It’s currently trading about -7.44% below its 52-week high.

Juno Therapeutics, Inc. Earnings Surprise

Juno Therapeutics, Inc. (JUNO) failed to surprise the stock market in its last reported earnings when it earned -$0.74 a piece versus the consensus-estimated -$0.73. Its revenue totaled $15.82 million down -18.16% from the previous quarter.

Juno Therapeutics, Inc. (NASDAQ:JUNO) Intraday View

This stock (JUNO) is ahead of its 52-week low with 148.46%. Its last month’s stock price volatility remained 5.15% which for the week stands at 4.09%. The share price has moved backward from its 20 days moving average, trading at a distance of -0.85% and stays 6.59% away from its 50 days moving average. Over the last five days, shares have managed 0.3% gains and now is up 52.74% since hitting its 200-day moving average of $31.48. Juno Therapeutics, Inc. (JUNO) has made its way to a 12-month gain of 65.58%.

Turning to Xencor, Inc. (NASDAQ:XNCR), its shares were trading at $19.78 a retreat of $-0.3, on the trading floor. The stock, after opening at $19.94, touched a high of $20.39 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.6. Xencor, Inc. has 3 buy ratings, 1 holds and 0 sells even after the stock tumbled -32.68% from its high of $ 29.38 to a $950.43 million market value through last close.

Xencor, Inc. (XNCR) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 1.6 to 1.6 during a month. Analysts set a 12-month price target of $31.2 a share. The target implies a 57.74% spike from where the shares are currently trading. Also, the current price highlights a discount of 82% to analysts’ high consensus price target.

Xencor, Inc. (NASDAQ:XNCR) Intraday Trading

The counter witnessed a trading volume of 0.22 million shares versus an average volume of 0.17 million shares during last trading session. Its last month’s stock price volatility remained 4.46% which for the week approaches 3.34%. The lowest price the stock reached in the last trading day was $19.45 and compares with the $18.45 52-week low. The stock recovered 7.21% since its low point and has performed -24.85% year-to-date.

Previous articleAnalysts Are Gushing Over Alder Biopharmaceuticals, Inc. (ALDR), Ocular Therapeutix, Inc. (OCUL)
Next articleAnalyst Stance On Two Stocks: Bioverativ Inc. (BIVV), Concert Pharmaceuticals, Inc. (CNCE)